"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,ES,T3,ES 2699532 T3,022-695-997-879-434,2019-02-11,2019,ES 12760157 T,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,Métodos y composiciones para mejorar la terapia antiangiogénica con anti-integrinas,Una combinación de un primer agente que es bevacizumab y un segundo agente que es un anticuerpo que se une específicamente a integrina beta 1 asociada con cualquier subunidad alfa e inhibe la unión de células tumorales a un sustrato extracelular y bloquea la unión de integrina beta 1 para uso en el tratamiento de un cáncer.,UNIV CALIFORNIA,CARBONELL WARREN;;AGHI MANISH,,https://lens.org/022-695-997-879-434,Granted Patent,no,0,0,16,16,0,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,C07K16/22;;A61P35/00;;C07K16/28,,0,0,,,,ACTIVE
2,EP,A4,EP 2688585 A4,113-636-337-090-373,2015-05-06,2015,EP 12760157 A,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS,,UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/113-636-337-090-373,Search Report,no,2,0,16,16,0,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/00;;A61K38/18;;A61K39/395;;A61K48/00,,7,6,131-093-768-517-177;;049-847-124-600-799;;022-165-741-064-962;;053-379-273-661-608;;005-227-081-513-279;;058-184-806-693-330,10.2174/187152010794728639;;21269250;;pmc3267166;;10.1016/s0002-9440(10)65005-5;;10751360;;pmc1876892;;18220791;;10.2174/138161207782794130;;10.1517/14728220902806444;;19335067;;pmc2940643;;10.1093/neuonc/nop073;;20156808;;10.1158/0008-5472.can-13-1742;;24327727;;pmc4160537,"CARLOS MAS-MORUNO: ""Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation"", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 1 December 2010 (2010-12-01), pages 753 - 768, XP055034886, Retrieved from the Internet <URL:http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/69969187.1/ben/acamc/2010/00000010/00000010/art00007/711E08525CEF25A8134434530600F42C4601B70289.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf> [retrieved on 20120807];;KIM S ET AL: ""Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin."", THE AMERICAN JOURNAL OF PATHOLOGY APR 2000, vol. 156, no. 4, April 2000 (2000-04-01), pages 1345 - 1362, XP002732579, ISSN: 0002-9440;;SATHORNSUMETEE SITH ET AL: ""Antiangiogenic therapy in malignant glioma: Promise and challenge"", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, vol. 13, no. 35, 1 January 2007 (2007-01-01), pages 3545 - 3558, XP002570212, ISSN: 1381-6128;;MILETIC H ET AL: ""Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms"", EXPERT OPINION ON THERAPEUTIC TARGETS,, vol. 13, no. 4, 1 April 2009 (2009-04-01), pages 455 - 468, XP009173289, ISSN: 1472-8222, DOI: 10.1517/14728220902806444;;SCOTT BRIAN J ET AL: ""Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors."", NEURO-ONCOLOGY JUN 2010, vol. 12, no. 6, June 2010 (2010-06-01), pages 603 - 607, XP002733159, ISSN: 1523-5866;;JAHANGIRI ARMAN ET AL: ""[beta]1 integrin: Critical path to antiangiogenic therapy resistance and beyond."", CANCER RESEARCH 1 JAN 2014, vol. 74, no. 1, 1 January 2014 (2014-01-01), pages 3 - 7, XP002733162, ISSN: 1538-7445;;See also references of WO 2012129448A1",ACTIVE
3,KR,A,KR 20140030153 A,166-646-745-880-093,2014-03-11,2014,KR 20137027236 A,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI- INTEGRINS,,UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/166-646-745-880-093,Patent Application,no,0,1,16,16,4,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K38/18;;A61K48/00;;A61P35/00,,0,0,,,,DISCONTINUED
4,CA,C,CA 2830908 C,168-674-557-914-71X,2019-09-24,2019,CA 2830908 A,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/168-674-557-914-71X,Granted Patent,no,0,0,16,16,0,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/395,,0,0,,,,ACTIVE
5,AU,B2,AU 2012/230809 B2,195-175-777-536-32X,2017-06-29,2017,AU 2012/230809 A,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,Methods and compositions for improving antiangiogenic therapy with anti-integrins,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/195-175-777-536-32X,Granted Patent,no,3,0,16,16,0,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/00;;A61K38/18;;A61K39/395;;A61K48/00,,0,0,,,,ACTIVE
6,EP,A1,EP 2688585 A1,004-839-014-537-87X,2014-01-29,2014,EP 12760157 A,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS,,UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/004-839-014-537-87X,Patent Application,yes,0,0,16,16,2,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/00;;A61K38/18;;A61K39/395;;A61K48/00,,0,0,,,,ACTIVE
7,AU,A1,AU 2012/230809 A1,017-854-306-127-36X,2013-10-10,2013,AU 2012/230809 A,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,Methods and compositions for improving antiangiogenic therapy with anti-integrins,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/017-854-306-127-36X,Patent Application,no,0,0,16,16,0,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/00;;A61K38/18;;A61K39/395;;A61K48/00,,0,0,,,,ACTIVE
8,US,A1,US 2014/0079637 A1,118-649-598-617-668,2014-03-20,2014,US 201214006669 A,2012-03-22,US 201214006669 A;;US 201161466791 P;;US 2012/0030204 W,2011-03-23,METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an anti-angiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR;;UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-07-16),https://lens.org/118-649-598-617-668,Patent Application,yes,5,0,16,16,2,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K49/00;;A61K39/395,424/9.1;;424/174.1;;424/133.1;;424/135.1;;424/136.1;;435/375,8,7,017-293-261-813-27X;;047-876-175-446-947;;034-052-640-439-66X;;086-239-971-100-421;;024-820-331-109-719;;048-843-807-158-317;;015-396-658-532-133,18469852;;10.1038/onc.2008.157;;pmc2832310;;pmc3719863;;10.1158/0008-5472.can-07-6390;;18519702;;10.1159/000097976;;17167269;;10.1111/j.1600-065x.1990.tb00561.x;;2142475;;10.1056/nejmoa0808268;;19196673;;8620517;;7508365;;10.1242/dev.119.4.1093,"Chekenya et al. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene (2008) 27, 5182-5194;;Park et al. beta1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts. Cancer Res. 2008 Jun 1; 68(11): 4398-4405.;;Carnevale et al. Regulation of Postangiogenic Neovessel Survival by beta1 and beta3 Integrins in Collagen and Fibrin Matrices. J. Vasc Res. 2007; 44:40-50.;;Hemler et al. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. (1990) Immunological Reviews 14:45-65.;;Tol et al. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. N Engl J Med 2009;360:563-72.;;Friedlander et al. Migration of Brain Tumor Cells on Extracellular Matrix Proteins in Vitro Correlates with Tumor Type and Grade and Involves Î±v, and Ã1 Integrins. CANCERRESEARCH56. 1939-1947. April 15. 19961;;Chen, Tom T, Context-dependent VEGF signaling: molecular regulation of vascular patterning during angiogenesis. University of California, Los Angeles . Dissertation, 2009, 235 pages.;;Yang et al. Embryonic mesodermal defects in 5 integrin-deficient mice. Development 119, 1093-1105 (1993)",DISCONTINUED
9,CN,A,CN 103561761 A,096-965-567-731-079,2014-02-05,2014,CN 201280024596 A,2012-03-22,US 2012/0030204 W;;US 201161466791 P,2011-03-23,Methods and compositions for improving antiangiogenic therapy with anti-integrins,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/096-965-567-731-079,Patent Application,no,3,0,16,16,0,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/00;;A61K38/18;;A61K39/395;;A61K48/00,,1,0,,,"D.E. HALL ET AL.: ""The α1/β1 and α6/β1 Integrin heterodimers mediate cell attachment to distinct sites on laminin"", 《THE JOURNAL OF CELL BIOLOGY》",DISCONTINUED
10,EP,B1,EP 2688585 B1,062-047-632-263-755,2018-09-05,2018,EP 12760157 A,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS,,UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/062-047-632-263-755,Granted Patent,yes,7,0,16,16,0,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,C07K16/22;;A61P35/00;;C07K16/28,,6,0,,,"Carlos Mas-Moruno: ""Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation"", Anti-Cancer Agents in Medicinal Chemistry, 1 December 2010 (2010-12-01), pages 753-768, XP055034886, Retrieved from the Internet: URL:http://docstore.ingenta.com/cgi-bin/ds _deliver/1/u/d/ISIS/69969187.1/ben/acamc/2 010/00000010/00000010/art00007/711E08525CE F25A8134434530600F42C4601B70289.pdf?link=h ttp://www.ingentaconnect.com/error/deliver y&format=pdf [retrieved on 2012-08-07];;KIM S ET AL: ""Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin."", THE AMERICAN JOURNAL OF PATHOLOGY APR 2000, vol. 156, no. 4, April 2000 (2000-04), pages 1345-1362, XP002732579, ISSN: 0002-9440;;SATHORNSUMETEE SITH ET AL: ""Antiangiogenic therapy in malignant glioma: Promise and challenge"", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, vol. 13, no. 35, 1 January 2007 (2007-01-01), pages 3545-3558, XP002570212, ISSN: 1381-6128;;MILETIC H ET AL: ""Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms"", EXPERT OPINION ON THERAPEUTIC TARGETS,, vol. 13, no. 4, 1 April 2009 (2009-04-01), pages 455-468, XP009173289, ISSN: 1472-8222, DOI: 10.1517/14728220902806444;;SCOTT BRIAN J ET AL: ""Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors."", NEURO-ONCOLOGY JUN 2010, vol. 12, no. 6, June 2010 (2010-06), pages 603-607, XP002733159, ISSN: 1523-5866;;JAHANGIRI ARMAN ET AL: ""[beta]1 integrin: Critical path to antiangiogenic therapy resistance and beyond."", CANCER RESEARCH 1 JAN 2014, vol. 74, no. 1, 1 January 2014 (2014-01-01), pages 3-7, XP002733162, ISSN: 1538-7445",ACTIVE
11,US,A1,US 2022/0111045 A1,057-596-782-683-764,2022-04-14,2022,US 202117512500 A,2021-10-27,US 202117512500 A;;US 201815869970 A;;US 201314006669 A;;US 2012/0030204 W;;US 201161466791 P,2011-03-23,Methods and Compositions for Improving Antiangiogenic Therapy with Anti-Integrins,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-07-16),https://lens.org/057-596-782-683-764,Patent Application,yes,1,0,16,16,2,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/395;;A61K49/00;;C07K16/22;;C07K16/28,,6,5,122-950-926-197-250;;026-098-979-275-223;;145-351-443-598-578;;069-344-589-625-364;;097-263-635-243-449,15705858;;10.1158/0008-5472.671.65.3;;pmc2917317;;10.1200/jco.2010.28.1386;;20606091;;pmc5654352;;10.1093/neuonc/nov019;;25665807;;10.2174/138161212802002661;;22591424;;22204725;;10.1056/nejmoa1103799,"Vlahakis et al. Integrin α9ß1 Directly Binds to Vascular Endothelial Growth Factor (VEGF)-A and Contributes to VEGF-A-induced Angiogenesis. JBC. 282(20):15187-15196, 2007. (Year: 2007);;Gerber and Ferrara. Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies. Cancer Res 2005; 65: (3). February 1, 2005. (Year: 2005);;Kindler et al. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617-3622. (Year: 2010);;Lassen et al. Phase 1 dose-escalation study of the anti-placental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-Oncology 17(7), 1007–1015, 2015. (Year: 2015);;Van der Bilt et al. Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance. Current Pharmaceutical Design, 2012, 18, 3784-3792. (Year: 2012);;Perren et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med; 365:2484-2496, Dec 29, 2011 (Year: 2011)",PENDING
12,WO,A1,WO 2012/129448 A1,113-672-234-669-145,2012-09-27,2012,US 2012/0030204 W,2012-03-22,US 201161466791 P,2011-03-23,METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA;;CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/113-672-234-669-145,Patent Application,yes,23,9,16,16,2,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/00;;A61K38/18;;A61K39/395;;A61K48/00,,12,11,026-016-888-835-414;;030-607-398-087-475;;006-574-964-805-278;;042-204-626-457-327;;045-094-249-115-990;;087-277-941-735-980;;060-974-282-226-886;;001-400-252-595-282;;007-499-303-589-95X;;040-417-488-869-812;;025-319-724-146-120,2547805;;10.1083/jcb.109.2.877;;pmc2115739;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;11254577;;10.1128/iai.69.4.2223-2229.2001;;pmc98149;;8918938;;10.1006/jmbi.1996.0598;;11036658;;10.1016/s0076-6879(00)26070-9;;10.1385/1-59259-240-6:349;;11968504;;18251716;;10.1042/bj20080078;;10.1083/jcb.105.3.1183;;2958481;;pmc2114793,"WERB, Z.; TREMBLE, P.; BERENSTEN, O.; CROWLEY, E.; DAMSKY, C. H.: ""Signal transduction through the fibronectin receptors induces collagenase expression"", J. CELL BIOL., vol. 109, 1989, pages 877 - 890;;DAMSKY, C. H.; FITZGERALD, M.; FISHER, S. J.: ""This provides a screening assay for potential antibodies. The immunogen used was whole human JAR choriocarcinoma cells"", THE ANTIBODY BLOCKS CELL ATTACHMENT TO FN, 1992;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;HEMACHANDRA ET AL.: ""Human Monoclonal Antibodies against Pseudomonas aeruginosa Lipopolysaccharide Derived from Transgenic Mice Containing Megabase Human Immunoglobulin Loci Are Opsonic and Protective against Fatal Pseudomonas Sepsis"", INFECTION AND IMMUNITY, vol. 69, no. 4, April 2001 (2001-04-01), pages 2223 - 2229, XP002204809, DOI: doi:10.1128/IAI.69.4.2223-2229.2001;;SCHIER ET AL.: ""Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site"", J MOL BIOL., vol. 263, no. 4, 8 November 1996 (1996-11-08), pages 551 - 67, XP029808944, DOI: doi:10.1006/jmbi.1996.0598;;TOMLINSON I.; HOLLIGER P.: ""Methods for generating multivalent and bispecific antibody fragments"", METHODS ENZYMOL, vol. 326, 2000, pages 461 - 479, XP001154118, DOI: doi:10.1016/S0076-6879(00)26070-9;;HOLLIGER, P.: ""Expression of antibody fragments in Pichia pastoris."", METH. MOL. BIOL., 2001;;FUJISAWA ET AL.: ""Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region"", BIOCHEM. J., vol. 411, 2008, pages 515 - 522;;J. CELL BIOL., vol. 105, no. 3, 1987, pages 1183 - 1190",PENDING
13,US,B2,US 11185585 B2,101-917-081-597-765,2021-11-30,2021,US 201815869970 A,2018-01-12,US 201815869970 A;;US 201314006669 A;;US 2012/0030204 W;;US 201161466791 P,2011-03-23,Methods and compositions for improving antiangiogenic therapy with anti-integrins,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-07-16),https://lens.org/101-917-081-597-765,Granted Patent,yes,40,1,16,16,2,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/00;;A61K39/395;;A61K49/00;;C07K16/22;;C07K16/28,,52,26,068-394-128-769-057;;033-184-343-057-284;;062-453-883-192-852;;076-011-838-179-499;;097-415-330-654-124;;120-449-130-170-456;;044-135-659-393-274;;095-250-948-302-870;;063-734-488-690-066;;034-052-640-439-66X;;017-293-261-813-27X;;028-502-659-121-553;;052-809-862-196-215;;032-682-432-004-809;;037-019-126-987-625;;086-239-971-100-421;;035-558-239-965-174;;101-153-143-847-989;;131-093-768-517-177;;053-379-273-661-608;;018-095-302-181-555;;022-165-741-064-962;;171-526-256-530-994;;005-227-081-513-279;;024-820-331-109-719;;015-396-658-532-133,10.1080/10623320600698037;;16728329;;18483304;;10.1158/1535-7163.mct-07-2154;;20215505;;10.1158/0008-5472.can-09-3730;;10.1093/jnci/94.19.1494;;pmc2975573;;12359858;;7544312;;10.1101/gad.9.15.1883;;10.1093/jnci/djq186;;20460633;;10.1073/pnas.91.6.2076;;pmc43312;;8134351;;23644530;;10.1158/0008-5472.can-13-0011;;pmc4040366;;10.1371/journal.pone.0005857;;pmc2689678;;19516901;;10.1159/000097976;;17167269;;18469852;;10.1038/onc.2008.157;;pmc2832310;;12743026;;pmc155986;;10.1093/emboj/cdg228;;12050630;;10.1038/417584a;;10980607;;10.1038/sj.onc.1203782;;10.1016/s0021-9258(17)31269-3;;2491849;;10.1111/j.1600-065x.1990.tb00561.x;;2142475;;10373119;;10.1126/science.284.5422.1994;;16061669;;10.1158/0008-5472.can-05-0161;;10.2174/187152010794728639;;21269250;;pmc3267166;;10.1517/14728220902806444;;19335067;;1384042;;pmc50065;;10.1073/pnas.89.19.9064;;18220791;;10.2174/138161207782794130;;20954324;;pmc2940643;;10.1093/neuonc/nop073;;20156808;;10.1056/nejmoa0808268;;19196673;;7508365;;10.1242/dev.119.4.1093,"Tysnes et al Stimulation of Gliom-cell migration by laminin and inhibition by anti-α3 and anti-β1 integrin antibodies. (Int. J. Cancer, 67:777-784 (1996)). (Year: 1996).;;Hu et al. Angiopoietin-2 induces Glioma cell invasion by stimulating MMP-2 expression through the beta1 integrin and FAK signaling pathways. Neuro-Oncology 6, 307-399, 2004. Abstract# AN-10. (Year: 2004).;;Färber et al. An α5β1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. Dec. 2008;39(4):579-85. (Year: 2008).;;Maglott et al. The α5β1 integrin is a therapeutic target for human glioblastoma and participates to chemoresistance. European Journal of Cancer, Supplement, (Jun. 2010) vol. 8, No. 5, pp. 55. Abstract No. 212. (Year: 2010).;;Brown et al. Regulatory effect of nerve growth factor in α9β1 integrin-dependent progression of glioblastoma. Neuro-Oncology 10, 968-980, 2008. (Year: 2008).;;Cordes et al. β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene (2006) 25, 1378-1390. (Year: 2006).;;Kawataki et al. Laminin isoforms and their integrin receptors in glioma cell migration and invasiveness: Evidence for a role of α5-laminin(s) and α3β1 integrin. Exp Cell Res. Nov. 1, 2007;313(18):3819-31. (Year: 2007).;;Senger et al. The α1β1 and α2β1 Integrins Provide Critical Support for Vascular Endothelial Growth Factor Signaling, Endothelial Cell Migration, and Tumor Angiogenesis. American Journal of Pathology, vol. 160, No. 1, Jan. 2002. (Year: 2002).;;Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium. 2006;13(2):113-135. (Year: 2006).;;Schiappacassi et al. p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Cancer Ther 2008;7(5):1164-75. (Year: 2008).;;Wolterink et al., Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma. Cancer Res; 70(6): 2504 Mar. 15, 2010. (Year: 2010).;;Zhu et al. Celastrol Acts as a Potent Antimetastatic Agent Targeting β1 Integrin and Inhibiting Cell-Extracellular Matrix Adhesion, in Part via the p38 Mitogen-Activated Protein Kinase Pathway. JPET 334:489-499, 2010. (Year: 2010).;;Wang et al Phenotypic Reversion or Death of Cancer Cells by Altering Signaling Pathways in Three-Dimensional Contexts (J Natl Cancer Inst 2002;94: 1494-1503). (Year: 2002).;;White et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell : Aug. 2004 (6): 159-170. (Year: 2004).;;Park et al. β1 Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and In vivo. Cancer Res. Feb. 1, 2006; 66(3): 1526-1535. (Year: 2006).;;Stephens, L. E., et al., Deletion of B1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev, Aug. 1, 1995:9(151:1883-95.. (Year: 1995).;;Carter, Andrea., Integrins as Target: First Phase III Trial Launches, but Questions Remain. JNCI: Journal of the National Cancer Institute, vol. 102, Issue 10, May 19, 2010, pp. 675-677. (Year: 2010).;;Kuppermann B.D, Inhibition of α5β1 Integrin in Neovascular AMD—A Phase 1 Study. IOVS, (Apr. 2010) vol. 51, No. 13, pp. 1252. (Year: 2010).;;Google search for AIIB2 antibody, p. 1-2. Apr. 7, 2021 (Year: 2021).;;Bobo et al. “Convection-enhanced deliver of macromolecules in the brain”, Proc. Natl. Acad. Sci., vol. 91, pp. 2076-2080, 1994.;;Carbonell et al. “131 integrin targeting potentiates antiangiogenic the growth of bevacizumab-resistant glioblastoma”, Cancer Res; 73(10); 3145-54, 2013.;;Carbonell et al. “The vascular basement membrane as “soil” in brain metastasis”, PLoS ONE, vol. 4, Issue 6, 14 pages, 2009.;;Carnevale et al. “Regulation of Postangiogenic Neovessel Survival by 131 and 133 Integrins in Collagen and Fibrin Matrices”, J. Vase Res.44:40-50, 2007.;;Chekenya et al. “The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling”, Oncogene; 27, 5182-5194, 2008.;;Chen “Context-dependent VEGF signaling: molecular regulation of vascular patterning during angiogenesis”, University of California, Los Angeles. Dissertation, 235 pages, 2009.;;Christofori “Changing neighbours, changing behauviour: cell adhesion molecule-mediated signalling during tumour progession”, The EMBO Journal, vol. 22, No. 10 pp. 2318-2323, 2003.;;ClinicaiTrials.gov. A Phase 1 b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC). Identifier: NCT00666692. 2008.;;CN Office Action, Application No. 2012800245968, dated Aug. 7, 2014.;;European Search Report, Application No. EP 12760157, dated Dec. 8, 2014.;;Friedlander et al. “Migration of Brain Tumor Cells on Extracellular Matrix Proteins in Vitro Correlates with Tumor Type and Grade and Involves alphav, and β1 Integrins”, Cancer Research; 56:1939-1947, 1996.;;Gura “Magic bullets hit the target”, Nature, vol. 417, pp. 584-586, 2002.;;Hall et al. “The alpha1/β1 and alpha6/β1 integrin heterodimers mediate cell attachment to distinct sites on laminin”, The Journal of Cell Biology, vol. 110, pp. 2175-2184, 1990.;;Hazlehurst et al. “Adhesion to ®bronectin via b1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)”, Oncogene; 19:4319-4327, 2000.;;Heino et al. “Regulation of cell adhesion receptors by transforming growth factor-beta”, The Journal of Biological Chemistry, vol. 264, pp. 380-388, 1989.;;Hemler et al. “Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions”, Immunological Reviews 14:45-65, 1990.;;Holash et al. “Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF”, Science, vol. 284, pp. 1994-1998, 1999.;;International Search Report and Written Opinion, PCT/US12/30204, dated Jun. 29, 2012.;;Jahangiri et al. “β1 integrin critical path to antiangiogenic therapy resistance and beyond”, Cancer Research, vol. 74, No. 1, pp. 3-7, 2014.;;JP Office Action, Patent Application No. 2014-501258, dated Feb. 9, 2016.;;Kim et al. “Regulation of angiogenesis in vivo by ligation of integrin alpha5 β1 with the central cell-binding domain of fibronectin”, The American Journal of Pathology, vol. 156, No. 4, pp. 1345-1362, 2000.;;Mardor et al. “Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring”, Cancer Res. 65:(15). pp. 6858-6863, 2005.;;Mas-Moruno et al. “Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation”, Anti-Cancer Agents in Medicinal Chemistry, 10, 753-768, 2010.;;Matsushita et al. “Neuropilin-1 interacts with integrin β1 and modulates pancreatic cancer cell growth, survival and invasion,” Annual Meeting of the Japanese Cancer Association, vol. 67th, p. 195, 2008. (Abstract).;;Miletic et al. “Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms”, Expert Opinion on Therapeutic Targets, vol. 13, No. 4, pp. 455-468, 2009.;;Park et al. “β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts”, Cancer Res. 68(11):4398-4405, 2008.;;Park et al. “β1 Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and In vivo,” Cancer Research 66(3), pp. 1526-1535, 2006.;;Petersen et al. “Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells”, Proc. Natl. Acad. Sci., vol. 89, pp. 9064-9068, 1992.;;Sathornsumetee et al. “Antiangiogenic therapy in malignant glioma: promise and challenge”, Current Pharmaceutical Design, vol. 13, No. 35, pp. 3545-3558, 2007.;;SATO “Anti-angiogenic drugs,” Japanese Journal of Clinical Medicine, vol. 68, No. 10, pp. 1825-1829, 2010. (Abstract).;;Scott et al. “Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors”, Neuro-oncology, vol. 12, No. 6, pp. 603-607, 2010.;;Tol et al. “Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer”, N. Engl. J. Med. 360:563-572, 2009.;;Yang et al. “Embryonic mesodermal defects in 5 integrin-deficient mice”, Development; 119:1093-1105, 1993.",ACTIVE
14,US,A1,US 2018/0236073 A1,156-141-281-246-089,2018-08-23,2018,US 201815869970 A,2018-01-12,US 201815869970 A;;US 201314006669 A;;US 2012/0030204 W;;US 201161466791 P,2011-03-23,Methods and Compositions for Improving Antiangiogenic Therapy with Anti-Integrins,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-07-16),https://lens.org/156-141-281-246-089,Patent Application,yes,0,0,16,16,2,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/395;;A61K39/00;;A61K49/00;;C07K16/22;;C07K16/28,,0,0,,,,ACTIVE
15,CA,A1,CA 2830908 A1,153-216-113-247-941,2012-09-27,2012,CA 2830908 A,2012-03-22,US 201161466791 P;;US 2012/0030204 W,2011-03-23,METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS,"Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.",UNIV CALIFORNIA,CARBONELL WARREN SHAWN;;AGHI MANISH KUMAR,,https://lens.org/153-216-113-247-941,Patent Application,no,0,0,16,16,0,A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61P35/00;;A61K39/395;;A61K38/18;;A61K48/00;;A61K2039/507;;C07K16/22;;C07K16/2842;;C12N2740/15043;;A61K2039/505;;A61K2039/545;;C07K2317/73;;A61K39/39558;;A61K49/00,A61K39/395,,0,0,,,,ACTIVE
16,WO,A1,WO 2001/005405 A1,187-341-971-343-856,2001-01-25,2001,US 0019162 W,2000-07-14,US 14407499 P,1999-07-16,FOLYLPOLYGLUTAMYL SYNTHETASE GENE TRANSFER TO ENHANCE ANTIFOLATE DRUG SENSITIVITY,"Methods of killing neoplastic cells are provided. The invention relates to the use of folylpolyglutamyl synthetase (FPGS) gene transfer to enhance the sensitivity of several types of tumor cells to polyglutamylatable antifolate drugs, such as methotrexate (MTX) and edatrexate (EDX).",GEN HOSPITAL CORP,AGHI MANISH;;KRAMM CHRISTOF M;;BREAKEFIELD XANDRA O,,https://lens.org/187-341-971-343-856,Patent Application,yes,0,9,1,2,0,A61K38/53;;A61K45/06;;A61K48/00;;A61K2121/00;;C12N9/93;;C12N2799/021;;C12N2799/022;;C12N2799/025;;C12N2799/027;;C12N2799/028;;A61K31/505;;Y02A50/30,A61K38/00;;A61K38/53;;A61K45/06;;A61K48/00;;C12N9/00,,4,4,039-436-987-905-003;;171-576-692-460-14X;;045-224-592-145-735;;064-707-284-555-287,10.1093/jnci/91.14.1233;;10413425;;9778690;;9312158;;10.1074/jbc.272.40.25373;;8521387,"AGHI M. ET AL.: ""Folypolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo"", J. NATL. CANCER INST., vol. 91, no. 14, 21 July 1999 (1999-07-21), pages 1233 - 1241, XP002931163;;MCGUIRE J.J. ET AL.: ""Folypolyglutamate synthetase expression in antifolate-sensitive and resistant human cell lines"", ONCOLOGY RESEARCH, vol. 10, no. 4, 1998, pages 193 - 200, XP002931164;;FREEMANTLE S.J. ET AL.: ""Transcription of the human folypoly-gamma-glutamate synthetase gene"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 40, 3 October 1997 (1997-10-03), pages 25373 - 25379, XP002931165;;TAYLOR S.M. ET AL.: ""Structural organization of the human folypoly-gamma-glutamate synthetase geen: Evidence for a singlegenomic locus"", CANCER RESEARCH, vol. 55, no. 24, 1995, pages 6030 - 6034, XP002931166",PENDING
17,US,B1,US 6770632 B1,160-023-009-592-203,2004-08-03,2004,US 61711600 A,2000-07-14,US 61711600 A;;US 14407499 P,1999-07-16,Folypolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity,"
    Methods of killing neoplastic cells are provided. The invention relates to the use of folylpolyglutamyl synthetase (FPGS) gene transfer to enhance the sensitivity of several types of tumor cells to polyglutamylatable antifolate drugs, such as methotrexate (MTX) and edatrexate (EDX). 
",GEN HOSPITAL CORP,AGHI MANISH;;KRAMM CHRISTOF M;;BREAKEFIELD XANDRA O,GENERAL HOSPITAL CORPORATION THE (2000-08-27),https://lens.org/160-023-009-592-203,Granted Patent,yes,12,11,1,2,0,A61K45/06;;A61K45/06;;A61K38/53;;A61K38/53;;Y02A50/30;;Y02A50/30,A61K38/53;;A61K45/06,514/44;;424/93.2;;435/320.1;;435/455;;435/456;;435/458;;435/459,65,62,106-386-562-055-571;;009-416-320-508-847;;185-525-004-577-968;;193-603-995-859-640;;144-625-282-558-100;;161-455-625-065-402;;132-014-380-609-655;;160-475-196-827-81X;;121-377-683-116-026;;022-894-404-158-642;;119-182-263-917-255;;016-710-417-045-35X;;062-454-033-921-97X;;008-685-157-530-911;;017-784-594-371-023;;039-436-987-905-003;;061-781-143-638-27X;;092-395-961-426-665;;042-647-058-351-921;;097-634-679-999-993;;015-585-302-194-72X;;049-870-597-924-772;;166-555-805-340-029;;091-890-938-877-101;;033-616-791-081-284;;046-748-437-273-335;;101-176-387-365-494;;045-224-592-145-735;;060-710-805-300-266;;037-212-494-742-503;;001-084-804-390-065;;069-201-580-559-411;;029-063-184-140-308;;191-175-949-438-086;;171-576-692-460-14X;;000-697-321-429-645;;031-118-187-392-620;;086-630-221-650-549;;080-787-242-731-417;;173-216-758-750-312;;054-413-946-186-69X;;072-862-608-446-985;;043-963-591-608-706;;135-929-415-919-181;;144-088-417-465-606;;024-262-182-773-689;;020-654-753-299-413;;128-134-658-730-284;;038-038-291-128-795;;017-422-113-127-954;;093-755-072-705-077;;004-780-045-023-077;;118-230-131-710-305;;018-165-346-104-093;;001-480-421-836-167;;064-707-284-555-287;;038-786-716-374-283;;041-865-502-049-825;;017-573-834-592-440;;096-209-313-393-248;;083-200-999-470-558;;011-956-180-765-276,7781922;;10.1096/fasebj.9.2.7781922;;9305836;;10.1038/38410;;10037199;;10.1517/13543776.8.1.53;;10.1016/s0021-9258(20)80592-4;;8408018;;8605241;;10.1016/0167-4781(95)00193-x;;10613797;;10.1038/71545;;9377566;;10.1016/s0378-5173(97)00423-7;;10.1016/s0958-1669(98)80033-5;;9821276;;10.1634/stemcells.18-1-19;;10661569;;10.1002/1097-4652(2001)9999:9999<::aid-jcp1060>3.0.co;2-h;;11241346;;11705842;;8882514;;10.1016/0248-4900(96)89122-2;;10.1111/j.1768-322x.1995.tb00937.x;;10.1093/jnci/90.5.370;;9498487;;10.1093/jnci/91.14.1233;;10413425;;10894261;;10.1002/(sici)1521-2254(200005/06)2:3<148::aid-jgm105>3.0.co;2-q;;1435744;;8973156;;10.1016/0168-9525(96)40049-x;;10.1172/jci112088;;pmc423952;;2413074;;10.1038/nbt0598-444;;9592392;;7834628;;9406237;;9426050;;7552983;;8221662;;8607030;;9312158;;10.1074/jbc.272.40.25373;;6186369;;10.1073/pnas.89.19.9151;;pmc50083;;1409616;;8408021;;10.1016/s0021-9258(20)80595-x;;9331089;;1371715;;2416428;;9778690;;10.1089/hum.1997.8.7-803;;9143906;;7543006;;10.1038/sj.gt.3300448;;9282176;;10.1615/critrevtherdrugcarriersyst.v12.i4.10;;9501965;;8620485;;9599306;;10.1111/j.1749-6632.1998.tb09644.x;;10.1007/978-1-4615-2960-6_134;;8304199;;2450647;;8729908;;8380127;;9516909;;9470229;;10.1016/s0167-7799(97)01137-2;;10.1089/hum.1997.8.1-73;;8989997;;10.1038/nm0996-985;;8782455;;8978404;;10.1093/jnci/89.1.21;;7592937;;10.1074/jbc.270.45.26918;;9054377;;10.1074/jbc.272.11.6903;;2369741;;3978616;;9147608;;10.1097/00001813-199701000-00001;;8521387;;8478137;;10.1002/ijc.2910540118;;10.1089/hum.1998.9.6-855;;9581908;;10.1089/hum.1994.5.8-969;;7948146;;8968096;;10.1007/bf00046349;;9034598;;9306402;;10.1038/nbt0997-871,"Miller et. al.; Targeted vectors for gene therapy, 1995, FASEB. J. 9: 190-199.*;;Verma et. al.; Gene therapy-promises, problems and prospects, 1997, Nature vol. 389: 238-242.*;;Dang et. al.; Gene Therapy and Translational Cancer Research, 1999, Clinical Cancer Research vol. 5: 471-474.*;;Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8(1): 53-69.*;;Osborne; Regulation of Folate and One-carbon Metabolism in Mammalian Cells, 1993, The Journal of Biological Chemistry, vol. 268, No. 29: 21657-21664.*;;Spinella et al., Molecular cloning of murine folypoly-gamma-glutamate synthetase, 1996, Biochemical Biophysical Acta, 1305(1-2): 11-4.*;;Hollon, T. Researchers and regulators reflect on first gene therapy death. Nature Medicine 6, p. 6, 2000.*;;Pawelek et al. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57:4537-4544, 1997.*;;Filion et al. Major limitations in the use of cationic liposomes for DNA delivery. International Journal of Pharmaceutics 162: 159-170, 1998.*;;Scherman et al. Application of lipids and plasmid design for gene delivery to mammalian cells. Curr. Opin. Biotechnol. 9:480-485, 1998.*;;Romano et al. Latest development in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18: 19-39, 2000.*;;Greco et al. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. Journal of Cellular Physiology 187:22-36, 2001.*;;Xu et al. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 7:3314-3324, 2001.*;;Abdallah, B. et al., ""Non-viral gene transfer: Applications in developmental biology and gene therapy,"" Biol. Cell 85:1-7 (1995).;;Aghi, M. et al., ""Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies,"" J. Natl. Cancer Inst. 90:370-380 (Mar. 1998).;;Aghi, M. et al., ""Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo,"" J. Natl. Cancer Inst. 91:1233-1241 (Jul. 1999).;;Aghi, M. et al., ""Prodrug activation enzymes in cancer gene therapy,"" J. Gene Med. 2:148-164 (May-Jun. 2000).;;Barredo, J. and Moran, R.G., ""Determinants of Antifolate Cytotoxicity: Folylpolyglutamate Synthetase Activity during Cellular Proliferation and Development,"" Molec. Pharmacol. 42:687-694 (1992).;;Calos, M.P. et al., ""The potential of extrachromosomal replicating vectors for gene therapy,"" Trends in Genetics 12:463-467 (1996).;;Chabner, B.A. et al., ""Polyglutamation of Methotrexate,"" J. Clin. Invest. 76:907-912 (1985).;;Chase, M. et al., ""An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,"" Nature Biotechnol. 16:444-448 (1998).;;Chen, L. and Waxman, D.J., ""Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy,"" Cancer Res. 55:581-589 (1995).;;Chu, E. and Allegra, C.J., ""Antifolates,"" Cancer Chemotherapy and Biotherapy: Principles and Practice, 2<nd >Edition, Chabner, B.A. and Longo, D.L., eds., Lippincott-Raven Publishers, New York, NY, pp. 109-148 (1996).;;Dachs, G.U. et al., ""Targeting Gene Therapy to Cancer: A Review,"" Oncol. Res. 9:313-325 (1997).;;Danks, M.K. et al., ""Overexpression of a Rabbit Liver Carboxylesterase Sensitizes Human Tumor Cells to CPT-11,"" Cancer Res. 58:20-22 (Jan. 1998).;;Deonarain, M.P. et al., ""Genetic Delivery of Enzymes for Cancer Therapy,"" Gene Therapy 2: 235-244 (1995).;;Drinkard, L. et al., ""A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG),"" Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).;;Freeman, S.M. et al., ""The 'Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified,"" Cancer Res. 53:5274-5283 (1993).;;Freeman, S.M. et al., ""In Situ Use of Suicide Genes for Cancer Therapy,"" Semin. Oncology 23:31-45 (1996).;;Freemantle, S.J. and Moran, R.G., ""Transcription of the Human Folylpoly-y-glutamate Synthetase Gene,"" J. Biol. Chem. 272:25373-25379 (1997).;;Fry, D.W. et al., ""Analysis of the Role of Membrane Transport and Polyglutamation of Methotrexate in Gut and the Ehrlich Tumor in Vivo as Factors in Drug Sensitivity and Selectivity,"" Cancer Res. 43: 1087-1092 (1983).;;Garrow, T.A. et al., ""Expression cloning of a human cDNA encoding folylpoly(lambda-glutamate) synthetase and determination of its primary structure,"" Proc. Natl. Acad. Sci. USA 89:9151-9155 (1992).;;Kim, J. S. et al., ""Regulation of Folate and One-carbon Metabolism in Mammalian Cells,"" J. Biol. Chem. 268:21680-21685 (1993).;;Lan, K-H, et al., ""In Vivo Selective Gene Expression and Therapy Mediated by Adenoviral Vectors for Human Carcinoembryonic Antigen-producing Gastric Carcinoma,"" Cancer Res. 57:4279-4284 (1997).;;Li, W.-W. et al., ""Mechanisms of Natural Resistance to Antifolates in Human Soft Tissue Sarcomas,"" Cancer Res. 52:1434-1438 (1992).;;Matherly, L.H. et al., ""Antifolate Polyglutamylation and Competitive Drug Displacement at Dihydrofolate Reductase as Important Elements in Leucovorin Rescue in L1210 Cells,"" Cancer Res. 46:588-593 (1986).;;McGuire, J.J. and Russell, C.A., ""Folylpolyglutamate Synthetase Expression in Antifolate-Sensitive and -Resistant Human Cell Lines,"" Oncology Res. 10:193-200 (1998).;;Miller, N. and Whelan, J., ""Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic Therapy,"" Hum. Gene Ther. 8:803-815 (1997).;;Moolten, F.L., ""Drug sensitivity (""suicide"") genes for selective cancer chemotherapy,"" Cancer Gene Ther. 1:279-287 (1994).;;Murdoch, B. et al., ""A rapid screening procedure for the identification of high-titer retrovirus packaging clones,"" Gene Ther. 4:744-749 (1997).;;Nakanishi, M. et al., ""Gene Introduction Into Animal Tissues,"" Crit. Rev. Therapeut. Drug Carrier Systems 12:263-310 (1995).;;O'Malley, Jr., B.W. et al., ""Combination Gene Therapy for Oral Cancer in a Murine Model,"" Cancer Res. 56:1737-1741 (1996).;;O'Malley, Jr., B.W. and Li, D., ""Combination Gene Therapy for Salivary Gland Cancer,"" Ann. N.Y. Acad. Sci. 842:163-170 (Apr. 1998).;;Peters, G.J. and van der Wilt, C.L., ""Development of a Simple Folylpolyglutamate Synthetase Assay in Tissues and Cell Lines,"" in Chemistry and biology of Pteridines and Folates, Ayling, J.E. et al., eds., Plenum Press, NY, pp. 651-654 (1993).;;Pizzorno, G. et al., ""Impaired Polyglutamylation of Methotrexate as a Cause of Resistance in CCRF-CEM Cells after Short-Term, High Dose Treatment with This Drug,"" Cancer Res. 48:2149-2155 (1988).;;Rainov, N.G. et al., ""Retrovirus-Mediated Gene Therapy of Experimental Brain Neoplasms Using the Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Paradigm,"" Cancer Gene Therapy 3:99-106 (1996).;;Ram, Z. et al., ""In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats,"" Cancer Res. 53:83-88 (1993).;;Rancourt, C. et al., ""Endothelial Cell Vehicles for Delivery of Cytotoxic Genes as a Gene Therapy Approach for Carcinoma of the Ovary,"" Clin. Cancer Res. 4:265-270 (Feb. 1998).;;Robbins, P.D. et al., ""Viral vectors for gene therapy,"" TIBTECH 16:35-40 (Jan. 1998).;;Rogulski, K.R. et al., ""Glioma Cells Transduced with an Escherichia coli CD/HSV-1 TK Fusion Gene Exhibit Enhanced Metabolic Suicide and Radiosensitivity,"" Human Gene Ther. 8:73-85 (1997).;;Roth, J.A. et al., ""Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer,"" Nature Med. 2:985-991 (1996).;;Roth, J.A. and Cristiano, R.J., ""Gene Therapy for Cancer: What Have We Done and Where are we Going?"" J. Natl. Cancer Inst. 89:21-39 (1997).;;Roy, K. et al., ""Different Antifolate-resistant L1210 Cell Variants with either Increased or Decreased Folylpolyglutamate Synthetase Gene Expression at the Level of mRNA Transcription,"" J. Biol. Chem. 270:26918-26922 (1995).;;Roy, K. et al., ""Posttranscriptionally Mediated Decreases in Folylpolyglutamate Synthetase Gene Expression in Some Folate Analogue-resistant Variants of the L1210 Cell,"" J. Biol. Chem. 272:6903-6908 (1997).;;Rumberger, B.G. et al., ""Differing Specificities for 4-Aminofolate Analogues of Folypolyglutamyl Synthetase from Tumors and Proliferative Intestinal Epiethelium of the Mouse with Significance for Selective Antitumor Action,"" Cancer Res. 50:4639-4643 (1990).;;Samuels, L.L. et al., ""Similar Differential for Total Polyglutamylation and Cytotoxicity among Various Folate Analogues in Human and Murine Tumor Cells in Vitro,"" Cancer Res. 45: 1488-1495 (1985).;;Takemura, Y. and Jackman, A.L., ""Folate-based thymidylate synthase inhibitors in cancer chemotherapy,"" Anti-Cancer drugs 8:3-16 (1997).;;Takemura, Y. et al., ""Altered Expression of Folylpolyglutamate Synthetase (FPGS) Gene in Human Leukaemia Cells with Defective Polyglutamation of Raltitrexed (ZD1694),"" Brit. J. Cancer 75(suppl. 1):31, Abstract No. P52 (1997).;;Taylor, S.M. et al., ""Structural Organization of the Human Folylpoly-mu-glutamate Synthetase Gene: Evidence for a Single Genomic Locus,"" Cancer Res. 55: 6030-6034 (1995).;;Terzis, A.J.A. et al., ""Proliferation, Migration and Invasion of Human Glioma Cells Exposed to Antifolate Drugs,"" Int. J. Cancer 54:112-118 (1993).;;Uckert, W. et al., ""Double Suicide Gene (Cytosine Deaminase and Herpes Simplex Virus Thymidine Kinase) but Not Single Gene Transfer Allows Reliable Elimination of Tumor Cells in Vivo,"" Human Gene Ther. 9:855-865 (Apr. 1998).;;Wei, M.X. et al., ""Experimental Tumor Therapy in mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 Gene,"" Hum. Gene Ther. 5:969-978 (1994).;;Yu, J.S. et al., ""Retroviral Delivery and Tetracycline-dependent Expression of IL-1beta-converting Enzyme (ICE) in a Rat Glioma Model Provides Controlled Induction of Apoptotic Death in Tumor Cells,"" Cancer Res. 56:5423-5427 (1996).;;Zhang, J. and Russell, S.J., ""Vectors for cancer gene therapy,"" Cancer & Metastasis Rev. 15: 385-401 (1996).;;Zufferey, R. et al., ""Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,"" Nature Biotechnol. 15:871-875 (1997).",EXPIRED
18,WO,A1,WO 2023/004396 A1,074-467-169-913-424,2023-01-26,2023,US 2022/0074024 W,2022-07-21,US 202163224330 P,2021-07-21,REGULATED VIRAL DELIVERY SYSTEMS AND THEIR USES,"Provided herein are recombinant virus systems comprising two or more coordinatedly regulated viral vectors. Methods for treating a cell proliferative disorder using these systems are also provided. The compositions and methods provided herein provide more efficient and coordinated delivery of larger transgenes and/or larger quantities of a transgene than previous methods by avoiding receptor interference and/or superinfection resistance, thereby enabling progressive replication of both vectors and efficient gene delivery by each vector.",UNIV CALIFORNIA,KASAHARA NORIYUKI;;COLLINS SARA A;;HADDAD ALEXANDER F;;AGHI MANISH;;LOGG CHRISTOPHER R,,https://lens.org/074-467-169-913-424,Patent Application,yes,1,0,1,1,13,C12N15/113;;A61P35/00;;C12N15/86;;C12N2740/13043;;C12N2800/40;;C12N2820/002;;C12N2830/001;;C12N2310/20,C12N15/867;;A61P35/00;;C12N15/113,,1,0,,,"ANONYMOUS: ""Tetracycline (Tet) Inducible Expression "", ADDGENE, 12 June 2021 (2021-06-12), XP093027677, Retrieved from the Internet <URL:https://www.addgene.org/collections/tetracycline/> [retrieved on 20230228]",PENDING
